PureTech Health plc (NASDAQ: PRTC) Stock Competitors & Peer Comparison
See PRTC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRTC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRTC | $17.38 | +2.12% | 4.2B | -3.78 | -$4.60 | N/A |
| VRTX | $521.12 | -1.47% | 132.3B | 27.38 | $19.03 | N/A |
| REGN | $807.65 | -0.33% | 83.2B | 17.70 | $45.63 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,002.31 | -0.47% | 62.3B | 90.46 | $11.08 | N/A |
| MRNA | $135.61 | -3.36% | 53.8B | -16.64 | -$8.15 | N/A |
| RVMDW | $11.71 | +1.12% | 46B | -1.33 | -$8.82 | N/A |
| RVMD | $207.68 | +0.17% | 44.2B | -23.55 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $351.00 | -0.14% | 37.5B | 61.80 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PRTC vs VRTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, VRTX has a market cap of 132.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while VRTX trades at $521.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas VRTX's P/E ratio is 27.38. In terms of profitability, PRTC's ROE is -0.32%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PRTC is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PRTC vs REGN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, REGN has a market cap of 83.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while REGN trades at $807.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas REGN's P/E ratio is 17.70. In terms of profitability, PRTC's ROE is -0.32%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
PRTC vs VRNA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PRTC's ROE is -0.32%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, PRTC is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
PRTC vs ARGX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ARGX has a market cap of 62.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ARGX trades at $1,002.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ARGX's P/E ratio is 90.46. In terms of profitability, PRTC's ROE is -0.32%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PRTC is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
PRTC vs MRNA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRNA has a market cap of 53.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRNA trades at $135.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRNA's P/E ratio is -16.64. In terms of profitability, PRTC's ROE is -0.32%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, PRTC is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PRTC vs RVMDW Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RVMDW has a market cap of 46B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RVMDW trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RVMDW's P/E ratio is -1.33. In terms of profitability, PRTC's ROE is -0.32%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, PRTC is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PRTC vs RVMD Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RVMD has a market cap of 44.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RVMD trades at $207.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RVMD's P/E ratio is -23.55. In terms of profitability, PRTC's ROE is -0.32%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, PRTC is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
PRTC vs SGEN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PRTC's ROE is -0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PRTC is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
PRTC vs ONC Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ONC trades at $351.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ONC's P/E ratio is 61.80. In terms of profitability, PRTC's ROE is -0.32%, compared to ONC's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PRTC vs ALNY Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ALNY has a market cap of 34.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ALNY trades at $258.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ALNY's P/E ratio is 46.49. In terms of profitability, PRTC's ROE is -0.32%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, PRTC is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PRTC vs ROIV Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ROIV has a market cap of 30.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ROIV trades at $41.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ROIV's P/E ratio is -39.78. In terms of profitability, PRTC's ROE is -0.32%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, PRTC is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
PRTC vs INSM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, INSM has a market cap of 27.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while INSM trades at $128.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas INSM's P/E ratio is -31.34. In terms of profitability, PRTC's ROE is -0.32%, compared to INSM's ROE of -1.11%. Regarding short-term risk, PRTC is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
PRTC vs INCY Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, INCY has a market cap of 25.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while INCY trades at $126.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas INCY's P/E ratio is 16.94. In terms of profitability, PRTC's ROE is -0.32%, compared to INCY's ROE of +0.30%. Regarding short-term risk, PRTC is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
PRTC vs BNTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BNTX trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BNTX's P/E ratio is -12.73. In terms of profitability, PRTC's ROE is -0.32%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, PRTC is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PRTC vs UTHR Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, UTHR has a market cap of 21.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while UTHR trades at $506.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas UTHR's P/E ratio is 18.13. In terms of profitability, PRTC's ROE is -0.32%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, PRTC is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
PRTC vs GMAB Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while GMAB trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas GMAB's P/E ratio is 24.90. In terms of profitability, PRTC's ROE is -0.32%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PRTC vs BGNE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PRTC's ROE is -0.32%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, PRTC is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PRTC vs DNA-WT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PRTC's ROE is -0.32%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, PRTC is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PRTC vs ASND Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ASND trades at $260.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ASND's P/E ratio is -107.77. In terms of profitability, PRTC's ROE is -0.32%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PRTC is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PRTC vs NBIX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while NBIX trades at $155.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas NBIX's P/E ratio is 22.42. In terms of profitability, PRTC's ROE is -0.32%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, PRTC is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PRTC vs JAZZ Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while JAZZ trades at $241.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, PRTC's ROE is -0.32%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, PRTC is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PRTC vs BBIO Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BBIO has a market cap of 14.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BBIO trades at $76.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BBIO's P/E ratio is -20.34. In terms of profitability, PRTC's ROE is -0.32%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, PRTC is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PRTC vs EXEL Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while EXEL trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas EXEL's P/E ratio is 16.67. In terms of profitability, PRTC's ROE is -0.32%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, PRTC is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PRTC vs SMMT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SMMT trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SMMT's P/E ratio is -15.66. In terms of profitability, PRTC's ROE is -0.32%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PRTC is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PRTC vs HALO Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while HALO trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas HALO's P/E ratio is 20.04. In terms of profitability, PRTC's ROE is -0.32%, compared to HALO's ROE of +1.81%. Regarding short-term risk, PRTC is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check HALO's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PRTC vs MDGL Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MDGL trades at $546.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MDGL's P/E ratio is -42.71. In terms of profitability, PRTC's ROE is -0.32%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, PRTC is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PRTC vs KRTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PRTC's ROE is -0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PRTC is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PRTC vs BMRN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BMRN trades at $64.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BMRN's P/E ratio is 30.97. In terms of profitability, PRTC's ROE is -0.32%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, PRTC is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BMRN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PRTC vs ARWR Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ARWR has a market cap of 11.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ARWR trades at $82.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ARWR's P/E ratio is -36.72. In terms of profitability, PRTC's ROE is -0.32%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PRTC is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PRTC vs TECH Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TECH trades at $72.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TECH's P/E ratio is 37.24. In terms of profitability, PRTC's ROE is -0.32%, compared to TECH's ROE of +0.09%. Regarding short-term risk, PRTC is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PRTC vs RNAM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PRTC's ROE is -0.32%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PRTC is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PRTC vs AXSM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, AXSM has a market cap of 10.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while AXSM trades at $210.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas AXSM's P/E ratio is -54.99. In terms of profitability, PRTC's ROE is -0.32%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, PRTC is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PRTC vs KRYS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KRYS trades at $348.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KRYS's P/E ratio is 43.62. In terms of profitability, PRTC's ROE is -0.32%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PRTC is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PRTC vs PRAX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PRAX has a market cap of 9.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PRAX trades at $345.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PRAX's P/E ratio is -26.71. In terms of profitability, PRTC's ROE is -0.32%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, PRTC is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PRAX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PRTC vs RXDX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PRTC's ROE is -0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PRTC is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RXDX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PRTC vs KYMR Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while KYMR trades at $115.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas KYMR's P/E ratio is -36.07. In terms of profitability, PRTC's ROE is -0.32%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PRTC is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PRTC vs PTGX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PTGX trades at $145.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PTGX's P/E ratio is 140.86. In terms of profitability, PRTC's ROE is -0.32%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, PRTC is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PRTC vs IONS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IONS trades at $56.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IONS's P/E ratio is -32.57. In terms of profitability, PRTC's ROE is -0.32%, compared to IONS's ROE of -1.11%. Regarding short-term risk, PRTC is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PRTC vs CYTK Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CYTK trades at $74.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CYTK's P/E ratio is -10.26. In terms of profitability, PRTC's ROE is -0.32%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, PRTC is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PRTC vs NUVL Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PRTC's ROE is -0.32%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PRTC is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PRTC vs CRNX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PRTC's ROE is -0.32%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PRTC is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
PRTC vs ABVX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ABVX has a market cap of 8.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ABVX trades at $119.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ABVX's P/E ratio is -62.62. In terms of profitability, PRTC's ROE is -0.32%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PRTC is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PRTC vs IMGN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PRTC's ROE is -0.32%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PRTC is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PRTC vs PCVX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PCVX trades at $59.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PCVX's P/E ratio is -7.80. In terms of profitability, PRTC's ROE is -0.32%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, PRTC is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check PCVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PRTC vs TXG Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TXG has a market cap of 8.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TXG trades at $67.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TXG's P/E ratio is -114.05. In terms of profitability, PRTC's ROE is -0.32%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PRTC is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PRTC vs IBRX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IBRX trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IBRX's P/E ratio is -8.31. In terms of profitability, PRTC's ROE is -0.32%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, PRTC is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PRTC vs TGTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TGTX trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TGTX's P/E ratio is 19.80. In terms of profitability, PRTC's ROE is -0.32%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, PRTC is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PRTC vs BPMC Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PRTC's ROE is -0.32%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PRTC is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PRTC vs APGE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas APGE's P/E ratio is -31.19. In terms of profitability, PRTC's ROE is -0.32%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PRTC is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PRTC vs CERE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, PRTC's ROE is -0.32%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PRTC is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PRTC vs IMVT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IMVT trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IMVT's P/E ratio is -13.74. In terms of profitability, PRTC's ROE is -0.32%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, PRTC is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check IMVT's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PRTC vs TWST Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TWST trades at $125.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TWST's P/E ratio is -56.54. In terms of profitability, PRTC's ROE is -0.32%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PRTC is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PRTC vs SYRE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SYRE has a market cap of 7.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SYRE trades at $86.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SYRE's P/E ratio is -44.58. In terms of profitability, PRTC's ROE is -0.32%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, PRTC is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
PRTC vs MTSR Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PRTC's ROE is -0.32%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PRTC is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PRTC vs BLTE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, BLTE has a market cap of 7.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while BLTE trades at $183.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas BLTE's P/E ratio is -97.95. In terms of profitability, PRTC's ROE is -0.32%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PRTC is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PRTC vs RYTM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RYTM has a market cap of 6.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RYTM trades at $101.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RYTM's P/E ratio is -32.50. In terms of profitability, PRTC's ROE is -0.32%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, PRTC is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
PRTC vs MRUS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PRTC's ROE is -0.32%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PRTC is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MRUS's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PRTC vs CAI Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CAI has a market cap of 6.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CAI trades at $24.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CAI's P/E ratio is 67.52. In terms of profitability, PRTC's ROE is -0.32%, compared to CAI's ROE of +0.19%. Regarding short-term risk, PRTC is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CAI's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PRTC vs ACLX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PRTC's ROE is -0.32%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PRTC is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PRTC vs RETA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, PRTC's ROE is -0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PRTC is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RETA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PRTC vs SRRK Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, SRRK has a market cap of 6.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while SRRK trades at $54.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas SRRK's P/E ratio is -15.83. In terms of profitability, PRTC's ROE is -0.32%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, PRTC is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
PRTC vs CGON Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CGON trades at $71.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CGON's P/E ratio is -26.75. In terms of profitability, PRTC's ROE is -0.32%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PRTC is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PRTC vs CNTA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PRTC's ROE is -0.32%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PRTC is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PRTC vs TVTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TVTX trades at $66.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TVTX's P/E ratio is -147.16. In terms of profitability, PRTC's ROE is -0.32%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, PRTC is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PRTC vs MIRM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MIRM trades at $98.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MIRM's P/E ratio is -6.76. In terms of profitability, PRTC's ROE is -0.32%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, PRTC is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PRTC vs DNTH Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DNTH trades at $107.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DNTH's P/E ratio is -25.79. In terms of profitability, PRTC's ROE is -0.32%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PRTC is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PRTC vs COGT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while COGT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas COGT's P/E ratio is -16.20. In terms of profitability, PRTC's ROE is -0.32%, compared to COGT's ROE of -0.73%. Regarding short-term risk, PRTC is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PRTC vs LGND Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while LGND trades at $288.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas LGND's P/E ratio is 31.62. In terms of profitability, PRTC's ROE is -0.32%, compared to LGND's ROE of +0.20%. Regarding short-term risk, PRTC is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PRTC vs XENE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while XENE trades at $58.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas XENE's P/E ratio is -12.55. In terms of profitability, PRTC's ROE is -0.32%, compared to XENE's ROE of -0.44%. Regarding short-term risk, PRTC is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PRTC vs PTCT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PTCT trades at $67.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PTCT's P/E ratio is -29.00. In terms of profitability, PRTC's ROE is -0.32%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, PRTC is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PRTC vs CDTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PRTC's ROE is -0.32%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, PRTC is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
PRTC vs ABCM Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PRTC's ROE is -0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PRTC is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ABCM's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
PRTC vs ORKA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ORKA has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ORKA trades at $91.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ORKA's P/E ratio is -47.16. In terms of profitability, PRTC's ROE is -0.32%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, PRTC is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ORKA's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PRTC vs ISEE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PRTC's ROE is -0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PRTC is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
PRTC vs ERAS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ERAS trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ERAS's P/E ratio is -16.88. In terms of profitability, PRTC's ROE is -0.32%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PRTC is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ERAS's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PRTC vs APLS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, PRTC's ROE is -0.32%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PRTC is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PRTC vs CRSP Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CRSP trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CRSP's P/E ratio is -11.23. In terms of profitability, PRTC's ROE is -0.32%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, PRTC is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PRTC vs DFTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while DFTX trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas DFTX's P/E ratio is N/A. In terms of profitability, PRTC's ROE is -0.32%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, PRTC is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check DFTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PRTC vs TERN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, PRTC's ROE is -0.32%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PRTC is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
PRTC vs ACAD Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ACAD trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ACAD's P/E ratio is 12.47. In terms of profitability, PRTC's ROE is -0.32%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, PRTC is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ACAD's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PRTC vs EWTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while EWTX trades at $43.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas EWTX's P/E ratio is -23.45. In terms of profitability, PRTC's ROE is -0.32%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, PRTC is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PRTC vs FOLD Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PRTC's ROE is -0.32%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PRTC is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check FOLD's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
PRTC vs PBLS Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while PBLS trades at $38.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas PBLS's P/E ratio is -44.05. In terms of profitability, PRTC's ROE is -0.32%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, PRTC is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check PBLS's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PRTC vs AKRO Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PRTC's ROE is -0.32%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PRTC is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PRTC vs ALPN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PRTC's ROE is -0.32%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PRTC is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
PRTC vs CELC Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CELC trades at $90.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CELC's P/E ratio is -20.95. In terms of profitability, PRTC's ROE is -0.32%, compared to CELC's ROE of -3.51%. Regarding short-term risk, PRTC is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check CELC's competition here
Opthea Limited (NASDAQ: OPT)
PRTC vs OPT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, PRTC's ROE is -0.32%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PRTC is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check OPT's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
PRTC vs TLX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TLX trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TLX's P/E ratio is 128.81. In terms of profitability, PRTC's ROE is -0.32%, compared to TLX's ROE of +0.07%. Regarding short-term risk, PRTC is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TLX's competition here
Veradermics, Incorporated (NYSE: MANE)
PRTC vs MANE Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MANE trades at $99.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MANE's P/E ratio is -31.76. In terms of profitability, PRTC's ROE is -0.32%, compared to MANE's ROE of -0.38%. Regarding short-term risk, PRTC is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check MANE's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PRTC vs MRTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PRTC's ROE is -0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PRTC is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
PRTC vs ELVN Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ELVN has a market cap of 4.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ELVN trades at $57.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ELVN's P/E ratio is -34.40. In terms of profitability, PRTC's ROE is -0.32%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, PRTC is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
PRTC vs RLAY Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RLAY trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RLAY's P/E ratio is -11.89. In terms of profitability, PRTC's ROE is -0.32%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, PRTC is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check RLAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PRTC vs ADPT Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while ADPT trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas ADPT's P/E ratio is -59.56. In terms of profitability, PRTC's ROE is -0.32%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, PRTC is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
PRTC vs TNGX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while TNGX trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas TNGX's P/E ratio is -28.92. In terms of profitability, PRTC's ROE is -0.32%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, PRTC is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PRTC vs CPRX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CPRX's P/E ratio is 12.30. In terms of profitability, PRTC's ROE is -0.32%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PRTC is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
PRTC vs VKTX Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while VKTX trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas VKTX's P/E ratio is -7.02. In terms of profitability, PRTC's ROE is -0.32%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, PRTC is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check VKTX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
PRTC vs IOVA Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while IOVA trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas IOVA's P/E ratio is -11.55. In terms of profitability, PRTC's ROE is -0.32%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, PRTC is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for PRTC.Check IOVA's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PRTC vs RYZB Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PRTC's ROE is -0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PRTC is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PRTC vs CBAY Comparison September 2026
PureTech Health plc (NASDAQ: PRTC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRTC stands at 4.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PRTC is priced at $17.38 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRTC currently has a P/E ratio of -3.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PRTC's ROE is -0.32%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PRTC is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PRTC.Check CBAY's competition here